BCRX (BioCryst Pharmaceuticals) Common Stock : $2.1 Mil (As of Dec. 2024)

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Common Stock?

BioCryst Pharmaceuticals's quarterly common stock increased from Jun. 2024 ($2.1 Mil) to Sep. 2024 ($2.1 Mil) and increased from Sep. 2024 ($2.1 Mil) to Dec. 2024 ($2.1 Mil).

BioCryst Pharmaceuticals's annual common stock increased from Dec. 2022 ($1.9 Mil) to Dec. 2023 ($2.1 Mil) and increased from Dec. 2023 ($2.1 Mil) to Dec. 2024 ($2.1 Mil).

BioCryst Pharmaceuticals Common Stock Historical Data

The historical data trend for BioCryst Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Common Stock Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

1.77

1.84

1.88

2.06

2.09

BioCryst Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															2.06	2.06	2.07	2.07	2.09

BioCryst Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

BioCryst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

BO1:Germany BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Executives

Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Amy E Mckee	director	4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie	director	4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin	director	ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle	officer: Chief Financial Officer	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson	director	C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer	officer: Vice President and CCO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes	officer: VP, General Counsel & Corp Sec	1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse	director, officer: CEO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones	officer: Exec Director, Finance - PAO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu	officer: VP Drug Discovery	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244